Based on the Ajanta Pharma Limited stock forecast from 3 analysts, the average analyst target price for Ajanta Pharma Limited is INR 1,465.00 over the next 12 months. Ajanta Pharma Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Ajanta Pharma Limited is Slightly Bullish , which is based on 9 positive signals and 5 negative signals. At the last closing, Ajanta Pharma Limited’s stock price was INR 1,308.25. Ajanta Pharma Limited’s stock price has changed by +0.65% over the past week, -0.33% over the past month and +14.56% over the last year.
No recent analyst target price found for Ajanta Pharma Limited
No recent average analyst rating found for Ajanta Pharma Limited
Company Overview
Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets finished dosages. The company markets and serves various therapeutic segments, such as anti-biotic, anti-malarial, anti-diabetic, cardiology, gynecology, pediatric, respiratory and general health products, dermatology, ophthalmology, and pain management areas. It also provides multivitamins, antibiotics, eye drops, cough syrups, etc. The company serves in India, Africa, rest of Asia, the United States, and internationally. It supplies its products to government bodies, including armed forces, government hospitals, canteens, stores department, etc. The company was founded in 1973 and is headquartered in Mumbai, India. Address: Ajanta House, Mumbai, India, 400067 Read Less
Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets finished dosages. The company markets and serves various therapeutic segments, such as anti-biotic, anti-malarial, anti-diabetic, cardiology,...Read More
Frequently Asked Questions About AJANTPHARM:NSE Stock
Based on ratings from 3 analysts Ajanta Pharma Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 5 buy, sell and hold ratings.
AJANTPHARM:NSE stock's dividend yield is 0.54%.
Our analysis grades AJANTPHARM:NSE stock's dividend yield at F. This means that AJANTPHARM:NSE stock's dividend yield
is above 33% of the stocks in the Drug Manufacturers-Specialty & Generic sector in the NSE exchange.
Based on this AJANTPHARM:NSE may be a poor dividend stock for its sector.
Based on targets from 3 analysts, the average taret price for AJANTPHARM:NSE is INR 1,465.00 over the next 12 months. The maximum analyst target price is INR 1520 while the minimum anlayst target price is INR 1385.
AJANTPHARM:NSE stock's Price/Earning ratio is 27.89.
Our analysis grades AJANTPHARM:NSE stock's Price / Earning ratio at F. This means that AJANTPHARM:NSE stock's Price/Earning ratio is above 53% of the stocks in the Drug Manufacturers-Specialty & Generic sector in the NSE exchange.
Based on this AJANTPHARM:NSE may be a overvalued for its sector.
The last closing price of AJANTPHARM:NSE's stock was INR 1,308.25.
The most recent market capitalization for AJANTPHARM:NSE is INR 162.55B.
Based on targets from 3 analysts, the average taret price for AJANTPHARM:NSE is projected at INR 1,465.00 over the next 12 months.
This means that AJANTPHARM:NSE's stock price may go up by +11.98% over the next 12 months.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AJANTPHARM:NSE !
Please login to proceed
Sorry - extended search is only available for registered users.
